204 related articles for article (PubMed ID: 37129912)
1. β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer.
Mohan DR; Borges KS; Finco I; LaPensee CR; Rege J; Solon AL; Little DW; Else T; Almeida MQ; Dang D; Haggerty-Skeans J; Apfelbaum AA; Vinco M; Wakamatsu A; Mariani BMP; Amorim LC; Latronico AC; Mendonca BB; Zerbini MCN; Lawlor ER; Ohi R; Auchus RJ; Rainey WE; Marie SKN; Giordano TJ; Venneti S; Fragoso MCBV; Breault DT; Lerario AM; Hammer GD
Cancer Res; 2023 Jul; 83(13):2123-2141. PubMed ID: 37129912
[TBL] [Abstract][Full Text] [Related]
2. A reappraisal of transcriptional regulation by NR5A1 and beta-catenin in adrenocortical carcinoma.
Lalli E
Front Endocrinol (Lausanne); 2023; 14():1303332. PubMed ID: 38155952
[TBL] [Abstract][Full Text] [Related]
3. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
4. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
5. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
6. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
Salomon A; Keramidas M; Maisin C; Thomas M
Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
[TBL] [Abstract][Full Text] [Related]
7. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
8. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract][Full Text] [Related]
9. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
11. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
14. Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process.
He H; Dai J; Yang X; Wang X; Sun F; Zhu Y
Biol Chem; 2018 May; 399(6):593-602. PubMed ID: 29730647
[TBL] [Abstract][Full Text] [Related]
15. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.
Heaton JH; Wood MA; Kim AC; Lima LO; Barlaskar FM; Almeida MQ; Fragoso MC; Kuick R; Lerario AM; Simon DP; Soares IC; Starnes E; Thomas DG; Latronico AC; Giordano TJ; Hammer GD
Am J Pathol; 2012 Sep; 181(3):1017-33. PubMed ID: 22800756
[TBL] [Abstract][Full Text] [Related]
16. RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
Liu-Chittenden Y; Jain M; Gaskins K; Wang S; Merino MJ; Kotian S; Kumar Gara S; Davis S; Zhang L; Kebebew E
Oncogene; 2017 Jun; 36(25):3541-3552. PubMed ID: 28114280
[TBL] [Abstract][Full Text] [Related]
17. Cushing's syndrome in an infant secondary to malignant adrenocortical tumors with somatic mutation of beta-catenin.
Pusantisampan T; Sangkhathat S; Kayasut K; Kanngurn S; Jaruratanasirikul S; Chotsampancharoen T; Kritsaneepaiboon S
Pediatr Dev Pathol; 2010; 13(3):238-42. PubMed ID: 19863445
[TBL] [Abstract][Full Text] [Related]
18. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
Fojo T; Huff L; Litman T; Im K; Edgerly M; Del Rivero J; Pittaluga S; Merino M; Bates SE; Dean M
BMC Med Genomics; 2020 Nov; 13(1):165. PubMed ID: 33148256
[TBL] [Abstract][Full Text] [Related]
19. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
20. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.
Gaujoux S; Grabar S; Fassnacht M; Ragazzon B; Launay P; Libé R; Chokri I; Audebourg A; Royer B; Sbiera S; Vacher-Lavenu MC; Dousset B; Bertagna X; Allolio B; Bertherat J; Tissier F
Clin Cancer Res; 2011 Jan; 17(2):328-36. PubMed ID: 21088256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]